



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07D 471/04, A61K 31/435 C07D 487/04, 491/048, 495/04 C07D 513/04, 498/04 A61K 31/495 // (C07D 471/04 C07D 221:00, 209:00)</p>	A1	<p>(11) International Publication Number: WO 94/06793</p> <p>(43) International Publication Date: 31 March 1994 (31.03.94)</p>
<p>(21) International Application Number: PCT/US93/08563</p> <p>(22) International Filing Date: 16 September 1993 (16.09.93)</p> <p>(30) Priority data: 07/947,152 18 September 1992 (18.09.92) US</p> <p>(71) Applicant: THE DU PONT MERCK PHARMACEUTICAL COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).</p> <p>(72) Inventor: WILKERSON, Wendell, Wilkie ; 106 Griffith Drive, New Castle, DE 19720 (US).</p> <p>(74) Agents: FATO, Gildo, E. et al.; The du Pont Merck Pharmaceutical Company, Legal/Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).</p>		<p>(81) Designated States: AU, BR, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, SK, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: 3,3'-DISUBSTITUTED-1,3-DIHYDRO-2H-PYRROLO[2,3-b]HETEROCYCLIC-2-ONE USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS OF MAN</p> <div style="text-align: center; margin: 20px 0;"> </div> <p>(57) Abstract</p> <p>Compounds of formula (I) have been shown to enhance the release of the neurotransmitters acetylcholine, dopamine and serotonin; and thus may be useful in the treatment of diseases of man where subnormal levels of this neurochemical are found such as in Alzheimer's disease and other conditions involving learning and cognition; and Parkinson's disease. The compounds of this invention can be described as shown in formula (I) where A is a heteroaromatic system.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

Title

3,3'-Disubstituted-1,3-dihydro-2H-pyrrolo[2,3-
b]heterocyclic-2-one Useful in the Treatment of
Cognitive Disorders of Man.

5

Background of the InventionField of Invention

10 This invention relates to disubstituted polycyclic
compounds, pharmaceutical compositions, processes for
preparation, and methods of use in mammals to treat
cognitive disorders and/or neurological dysfunction
and/or mood disturbances such as, but not limited to
15 degenerative nervous system diseases. Additionally,
these compounds can be used as reagents in studies on
the biochemical mechanism of neurotransmitter based
diseases.

20


Background Including Prior Art

Increasingly there is a need for effective
treatments for nervous system disorders and neurological
deficiencies. Many of these diseases correlate with
increasing age, due mainly to degenerative changes in
25 the nervous systems. Although in early stages of some
diseases certain systems are rather specifically
affected (e. g. cholinergic systems in Alzheimer's
Disease and Myasthenia Gravis, the dopaminergic system
in Parkinson's Disease, etc.), multiple neurotransmitter
30 system deficiencies (acetylcholine, dopamine,
norepinephrine, serotonin) is generally found at later
stages of disease such as senile dementia, multi-infarct
dementia, Huntington's Disease, mental retardation, etc.
This explains the generally observed multiple
35 symptomatology that includes cognitive, neurological,
and effective/psychotic components (see Gottfries,

Psychopharmacol, 1985, 86, 245). Deficits in the synthesis and release of acetylcholine in the brain are generally thought to be related to cognitive impairment (see Francis, et al., New England J. Med., 1985, 7, 313) whereas neurological deficits (e. g. Parkinsonian symptoms) and mood/mental changes may be related to impairment of dopaminergic and serotonergic systems, respectively. Other neurological deficits (e. g. Myasthenia Gravis) are related to cholinergic deficiencies in the peripheral nervous system.

Treatment strategies employed previously encompass vasoactive drugs like vincamine and pentoxifylline; metabolic enhancers like ergoloid mesylates, piracetam, and naftidrofuryl; neurotransmitter precursors like l-DOPA, choline, and 5-hydroxytryptamine; transmitter metabolizing enzyme inhibitors such as physostigmine; and neuropeptides like adrenocorticotrophic hormone and vasopressin-related peptides. Except for l-DOPA treatment for Parkinson's Disease and cholinesterase inhibitor treatment for Myasthenia Gravis, these treatment strategies have generally failed to enhance the residual function of the affected systems by enhancing the stimulus-induced release of neurotransmitters. Theoretically, such an enhancement would improve the signal-to noise ratio during chemical transmission of information, thereby reducing deficits in processes related to cognition, neurological function, and mood regulation.

The most pertinent literature citations and patent references related to this invention can be found in DeNoble, et al., Pharmacol. Biochem. Behavior, 1990, 36, 957; Cook, et al., 1990, 19, 301; Nickolson, et al., 1990, 19, 285; and Myers and Nickolson United States Patent 4,760,083 (1988), and the references therein. These references describe and teach that a,a-disubstituted aromatic or heteroaromatic of the formula:



or a salt thereof


wherein X and Y are taken together to form a saturated or unsaturated carbocyclic or heterocyclic first ring and the shown carbon in said ring is a to at least one additional aromatic ring or heteroaromatic ring fused to the first ring;

one of Het¹ or Het² is 2, 3 or 4-pyridyl; or 2, 4 or 5-pyrimidinyl, and the other is selected from

- (a) 2, 3 or 4-pyridyl
- (b) 2, 4 or 5-pyrimidinyl
- (c) 2-pyrazinyl
- (d) 3 or 4-pyridazinyl,
- (e) 3 or 4-pyrazolyl,
- (f) 2 or 3-tetrahydrofuranyl, and
- (g) 3-thienyl

are useful as cognition enhancers.


Patent WO 91/01/306, Feb. 7, 1991 discloses oxoindole derivatives of formula:



useful for treating senile dementia, i. e improving brain functions and activating and protecting brain metabolism. In the above formula, R¹ represents hydrogen, halogen lower alkyl, or lower alkoxy; R₂ represents hydrogen or lower alkyl; R³ represents -CH₂-R⁵, wherein R⁵ represents alkyl which maybe cyclic, benzodioxanyl, or phenyl which may be substituted with a plurality of hydrogen, lower alkyl, lower alkoxy,

hydroxy, ethylamino, trifluoromethyl, nile, nitro,
 or benzyloxy; alternatively R^2 and R^3 may be combined
 together to form $=CH-R^5$, wherein R^5 is defined above;
 and R^4 represents 1-propylbutyl, pyridyl, or phenyl or
 5 substituted phenyl.

EP 415102-A discloses a series of 1,3-dihydro-1-
 (pyridinylamino)-2H-indol-2-ones as having analgesic,
 anticonvulsant, and/or memory enhancing activity and are
 useful in the treatment of Alzheimer's disease.




where R^1-R^3 = H, lower alkyl (opt. substd. by aryl);
 methyl or ethyl substituted by pyridyl or thienyl;
 or aryl; or $R^2 + R^3$ completes 4-6 carbon cycloalkane
 or spiro fused arene, piperidine or tetrahydropyran;
 X and Y = H, halo, lower alkyl, lower alkoxy, NO_2 , NH_2 ,
 or CF_3 ;

m and n = 1-3;

lower = 1-6 carbon

Ting, et al., in EP 0347698 A1, described a series
 of heterobicyclic compounds having antiinflammatory
 activity with formula



where **A** represents a fused 5- or 6-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms in the ring, each heteroatom independently represents O, S, N or NR⁶ where R⁶ is the group NR⁶ is H or C₁ to C₄ alkyl; the double lines represent optional double bond, such that when the bond to X is double, X is O or S; and when the bond to X is a single bond, X is OR¹⁰ where R¹⁰ is alkyl or aralkyl; T² and T³ independently represent S, SO or SO₂; m and n independently represent 0 or 1; and R¹ is H, alkyl, aryl, or aralkyl; R² and R³ independently represent H, alkyl, halogen, aryl or aralkyl, etc.


Summary of the Invention

It has been found that certain polycyclic compounds having 'mixed pendant groups' gem substitutions enhance the stimulus-induced release of neurotransmitters, specifically acetylcholine, dopamine and serotonin in nervous tissues, and thus improve processes involved in learning and memorization of an active avoidance task.

20


Most particularly, according to the present invention there is provided a pharmaceutical composition consisting essentially of a pharmaceutically suitable carrier and an effective amount of a compound of the formula

25



Formula I

Preferred Embodiment are compounds of **Formula I** where **A** is



R^1 is $(CH_2)_m-W$ or $(CH_2)_n-R^4$;

5 R^2 is alkyl of 1-7 carbons, benzyl substituted with 0-3 R^4 , or phenyl substituted with 0-3 R^5 ;

R^3 is H, alkyl of 1-6 carbons, halogen, CN, OR^7 , $N(R^7R^8)$, $S(O)pR^7$, NO_2 , or CF_3 ;

10 R^4 is CO_2R^7 , $CON(R^7R^8)$, CN, OR^7 , $N(R^7R^8)$, $S(O)pR^7$, F, Cl, Br, NO_2 , or COR^7 ;

15 R^5 is CO_2R^7 , $CON(R^7R^8)$, CN, OR^7 , $N(R^7R^8)$, $S(O)pR^7$, F, Cl, Br, NO_2 , COR^7 , or CF_3 ;

R^6 is H, alkyl of 1-4 carbons, phenyl, or benzyl;

20 R^7 and R^8 independently are H, or alkyl of 1-6 carbons;

W is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, tetrahydrofuranyl, thienyl, or phenyl optionally substituted with 0-2 R^5 ;


25 m is 1 to 4;

n is 1 to 6; and

p is 0 to 2.

30 Most preferred compounds of **Formula I** are those where

A is



35 R^1 is $(CH_2)_m-W$ or $(CH_2)_n-R^4$;

R^2 is alkyl of 1-7 carbons, benzyl substituted with 0-3 R^4 , or phenyl substituted with 0-3 R^5 ;

40 R^3 is H, alkyl of 1-4 carbons, halogen, CN, OR^7 , $N(R^7R^8)$, $S(O)pR^7$, NO_2 , or CF_3 ;

45 R^4 is CO_2R^7 , $CON(R^7R^8)$, CN, $S(O)pR^7$, or COR^7 ;

R^5 is CO_2 , $CON(R^7R^8)$, CN , OR^7 , $N(R^7R^8)$, pR^7 , F , Cl , Br , NO_2 , COR^7 , or CF_3 ;

R^6 is H , alkyl of 1-4 carbons, phenyl, or benzyl;

R^7 and R^8 independently are H , or alkyl of 1-6 carbons;

W is pyridyl, pyrimidinyl, tetrahydrofuranlyl;

m is 1 to 4;

n is 1 to 6; and

p is 1 or 2.

Specifically preferred compounds of **Formula I** are:

a. 1,3-Dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one Dihydrochloride,

b. 1,3-Dihydro-1-(4-chlorophenyl)-3,3-bis(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one Dihydrochloride,

c. 1,3-Dihydro-1-(4-chlorophenyl)-3-(3-cyanophenyl)-3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one Dihydrochloride,

d. 1,3-Dihydro-1-(4-chlorophenyl)-3-(3-pyridinylmethyl)-3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one Dihydrochloride,

e. 1,3-Dihydro-1-(4-chlorophenyl)-3-(phenylmethyl)-3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one,

Detail Description of the Invention Synthesis

Most of the compounds of this invention can be synthesized by the sequence shown in **Schemes 1** and **2**.

Generally, when R_1 is 4-picolyl, the compounds are

prepared as shown in **Scheme 1**, where the lactam **IIA** is

reacted with excess 4-picolyl chloride under phase transfer conditions to give desired product. The phase transfer catalyst can be , but not limited to, tetrabutylammonium- iodide, chloride, or hydroxide.


5 Depending on the facility of forming the anion at the 3-position of the lactam, **IIA** can be reacted with bases such as , but not limited to sodium or potassium bicarbonate, sodium or potassium carbonate, sodium, potassium, or lithium hydroxide, or any other base

10 compatible with an organic-aqueous solvent system. The solvent system may be composed of water and an organic solvent which is not miscible with water such as but not limited to benzene, toluene, hexane, methyl cyclohexane, or methylene chloride. The reaction can be conducted at

15 temperatures ranging from 4°C to solvent reflux temperature. The reaction of **IIA** with excess 4-picolyl chloride can be conduct in non aqueous, aprotic solvents by forming the anion of IIA with excess bases such as, but not limited to, sodium or potassium hydride, n-butyl


20 lithium, or sodium bis(trimethylsilyl) amide. The aprotic solvent can be, but not limited to, tetrahydrofuran, dioxane, dimethoxyethane, dimethylformamide, dimethylacetamine, or benzene.

Scheme 1 Synthesis of 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo [2.3-b]heterocyclic-2-one when R¹ is 4-picolyl.



II A

Scheme 2. Synthesis of 3,3'-disubstituted-1,4-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one when R^1 is other than 4-picolyl.



Alternatively, compounds of **Formula** can be prepared by reacting **III** with strong bases such as but not limited to, sodium or potassium hydride, n-butyl lithium, or sodium bis(trimethylsilyl) amide in an
5 aprotic solvent such as, but not limited to, tetrahydrofuran, dioxane, dimethoxyethane, dimethylformamide, dimethylacetamine or benzene. This approach can be seen in **Scheme 2**.

The starting lactam can be prepared as described
10 by:


- a. Marfat, et al., Tetrahedron Lett., **1987**, 28(35); 4027-4030
- b. R. P. Robinson and K. M. Donahue, J. Org. Chem.,
15 **1991**, 56, 4805-4806
- c. Ting, et al., J. Med. Chem., **1990**, 33, 2697-2706;
- d. Stingach, et al., Chemistry of Heterocyclic Compounds, **1981**, 1, 54-56
- 20 e. Royer, et al., Tetrahedron, 1980, 36, 2499-2465
- f. Schafer and Gewald, Monatsh. Chem., 1989, 120(4), 315-322
- g. Wolfe, et al., J. Am. Chem. Soc., 1980, 102(10), 3646-3647
- 25 h. By using a combination of the method described by Taylor, et al., Tetrahedron, **1987**, 43(21), 5145-5158, "Intramolecular Diels-Alder Reactions of 1,2,4-Triazines. A General Synthesis of Furo [2,3-b]-Dihydropyrano[2,3-b]Pyridines, and Pyrrol[2,3]Pyridines", and the method described by Stingach, et al., Khimiya Geterotsiklicheskikh Soedinenii, **1981**, 1, 54-56, "Thiosemicarbozones of 7-Azasatin Derivatives" or the method described by Robinson and Donahue, J. Org. Chem., **1991**, 56, 4805-4806, "Synthesis of 5-Azaoxindole", the desired starting materials could be made.
- i. Fortunak, US 4997954, 05 Mar 1992

- j. T , et al., in EP 0347698 A1, a: references therein.
- k. Beugelmans and Roussi, Chem. Commun., 1979, 950
- l. Goehring, Wolfe, et al., J. Am. Chem. Soc.,
5 1985, 107, 435
- m. Clark, et al., Synthesis (1991), 10, 871-878.

The compounds of this invention can exist as free bases or acid addition salts of pharmaceutically
10 acceptable acids. Further, the compounds of this invention, where R^1 is other than 4-picolyl, can exist as racemates, or the separate enantiomers; diastereomers if R^1 contains a chiral center(s); or syn or anti or E or Z, or mixtures thereof if R^1 contains a moiety
15 capable of forming geometric isomers.

Synthesis

Preparation 1.




5

1,3-Dihydro-1-phenyl-2H-pyrrolo[2,3-b]pyridin-2-one

10 The compound was prepared as described by Ting,
Kaminski, et al., in "Substituted 1,3-Dihydro-2H-
pyrrolo[2,3-b]pyridin-2-ones as Potential
Antiinflammatory Agents", J. Med. Chem., **1990**, 33,
2697-2706 in 55% yield; mp 116.0-117.0°C; IR(KBr): 1727
15 cm⁻¹ (CO); ¹H NMR(CDCl₃ TMS): δ 3.73 (s, 2H, CH₂-CO),
[7.00 (dd, 1H), 7.39 (dd, 1H), 8.18 (d, 1H), 2,3-subst.
Pyr], 7.51 (m, 5H, Phe); mass spec m/e 211 (M+1); Anal
calcd for C₁₃H₁₀N₂O, MW 210.24: C, 74.27; H, 4.79; N,
13.33. Found: C, 74.11; 4.73; N, 12.92.

20 Other "heterocyclic " can be prepared using a
modification of the teaching of Ting, et al., EP
0347698, 1989.

 1,3-Dihydro-1-(4-chlorophenyl)-2H-pyrrolo[2,3-
b]pyridin-2-one was prepared as taught in EP 0347698:
25 mp 154-155°C; lit mp 148-150°C.


Example 1.

**1,3-Dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-
2H-
pyrrolo[2,3-b]pyridin-2-one Dihydrochloride
Hemihydrate**

A suspension of NaH (0.55 g, 22.9 mmol) in 25 ml dry THF was treated with **Prep 1** (1,3-dihydro-1-phenyl-2H-pyrrolo[2,3-b]pyridin-2-one) (1.0 g, 4.76 mmol) and stirred under argon for 30 min at room temperature. The mixture was then treated with excess 4-picolyl chloride hydrochloride (2.5 g, 15.2 mmol) and stirred for an additional 3 h while under argon. The mixture was refluxed for 30 min, cooled to room temperature, and carefully partitioned between 200 ml CH₂Cl₂ and 200 ml water. The organic layer was washed with 2 X 100 ml water and brine, dried over MgSO₄, filtered, and concentrated to an oil which was found to be impure by TLC (CHCl₃-MeOH, 9:1). The oil was chromatographed on silica gel using CHCl₃-MeOH (9:1) as mobile phase. Appropriate fractions were combined and treated with 1N HCl/Et₂O, and concentrated at reduced pressure to give the desired product as an amorphous off-white solid in 37.7% (0.85 g) yield; mp 184.0-185.0°C; IR(nujol): 1716 cm⁻¹ (CO); ¹H NMR(DMSO-d₆ TMS): δ, [3.67 (d, 2H), 3.76 (d, 2H), CH₂-C-CH₂], [6.87 (d, 4H), 8.60 (d, 4H) two 4-Pyr], [7.38 (m, 1H), 8.00 (d, 1H), 8.20 (d, 1H), 2,3-

disubs. P, 7.41 (m, 5H, Phe); mass spec m/e 392(M+1),
 Anal calcd for $C_{25}H_{20}N_4O \cdot 2HCl \cdot 0.5H_2O$, MW 474.39: C,
 63.30; H, 4.89; N, 11.81. Found: C, 63.43; H, 4.69; N,
 11.68.


5

Example 2

10 **1,3-Dihydro-1-(4-chlorophenyl)-3,3-bis(4-**
 pyridinylmethyl)-2H-
 pyrrolo[2,3-b]pyridin-2-one Dihydrochloride

By substituting 1-(4-chlorophenyl)-1,3-dihydro-2H-
 15 pyrrolo[2,3-b]pyridin-2-one (Ting, et al. EP 0347698A)
 in **Ex 1**, the desire product was obtained in 64% yield;
 mp 137°C dec.; IR(nujol): 1718 cm^{-1} (CO); 1H NMR(DMSO- d_6
 TMS): d [3.70 (d, 2H), 3.93 (d, 2H), CH_2-C-CH_2], [7.1
 (m, 1H), 7.5 (d, 1H), 8.35 (d, 1H), Pyr], [7.65 (d, 2H),
 20 8.77 (2H), 4-Cl-Phe], [8.10 (d, 4H), 8.95 (d, 4H), 2 4-
 Pyr]; mass spec m/e 427(M+1).

Preparation 2



5

A mixture of 1,3-dihydro-1-phenyl-2H-pyrrolo[2,3-b]pyridin-2-one (3.2 g, 15.22 mmol) and pyridine-4-carboxaldehyde (1.63 g, 15.22 mmol) in 50 ml EtOH was treated with triethylamine (1 g) and stirred at room temperature for 16 h. The mixture was diluted with an additional 100 ml EtOH, heated to 80°C, and placed in the cold for 24 h. The resulting solid was collected by filtration, washed with cold EtOH, and dried to give the a,b-unsaturated amide in 99% (4.5 g) yield; mp 199-200°C; IR(nujol): 1723 (CO) cm^{-1} ; ^1H NMR(CDCl_3 TMS): δ [6.88 (m, 1H); 7.71 (d, 1H), 8.16 (d, 1H) 2,3-disubst. Pyr], [7.40 (m, 2H), 7.53 (m, 3H), Phe], [7.48 (d, 2H), 8.76 (d, 2H) 4-Pyr], 7.88 (s, 1H, C=CH); mass spec m/e 300(M+1).


20

The a,b-unsaturated amide (**Prep 2B**) (4.0 g, 13.36 mmol) in 100 ml dry THF was treated with NaBH_4 (0.51 g, 13.48 mmol) and stirred at room temperature for 16 h. The mixture was refluxed for 1 h, cooled to room temperature, treated with 25 ml acetic acid, and concentrated in vacuo. The residue was partitioned between 150 ml CH_2Cl_2 and 50 ml saturated NaHCO_3 , and the organic phase was washed with water and brine, dried over anhydrous MgSO_4 , filtered, concentrated in vacuo to give the desired product (**Prep 2C**) as a homogeneous (TLC,

30

CHCl₃-MeOH, 9:1) glass in 94% (3.80 g); IR, CHCl₃ film): 1726 (CO) cm⁻¹; ¹H NMR(CDCl₃ TMS): d [3.22 (2d, 1H), 3.50 (2d, 1H) CH₂-Pyr], 3.96 (m, 1H, CH), [6.93 (dd, 1H), 7.25 (m, 1H), 8.12 (d, 1H), 2,3-disubst. Pyr], 7.0-7.4 (m, 5H, Phe), [7.41 (d, 2H), 8.48 (d, 2H), 4-Pyr]; mass spec m/e 302(M+1).


Preparation 3



15 **1,3-Dihydro-1-(4-chlorophenyl)-3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one**

By substituting 1,3-dihydro-1-(4-chlorophenyl)-2H-pyrrolo[2,3-b]pyridin-2-one in **Prep 2**, the desired intermediate (**3C**) was prepared in an average yield of 85%; mp 177-179°C dec.; IR(nujol): 1732 cm⁻¹ (CO); ¹H NMR(CDCl₃ TMS): d [3.41 (m, 1H), 3.52 (m, 1H), CH₂-Pyr], 4.03 (t, 1H, CH-C-Pyr), [7.02 (m, 1H), 7.3 (M, 1H), 8.18 (d, 1H) 2,3-Pyr], 7.35 (m, 4H, Phe-Cl), 7.35, 8.46 (2d, 4H, 4-Pyr); mass spec m/e 336(M+1).

25


Example 3

**5 1,3-Dihydro-1-(4-chlorophenyl)-3-(3-cyanophenyl)-
3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-
one Dihydrochloride**

The solution of 1,3-dihydro-1-(4-chlorophenyl)-3-
10 (4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one (3.0
g, 8.93 mmol) in 75 ml dry THF was treated with NaH
(0.26 g, 10.7 mmol) and stirred at room temperature for
30 min. The mixture was then treated dropwise with a
solution of *α*-bromo-*m*-tolunitrile (1.93 g, 9.82 mmol)
15 dissolved in 25 ml dry THF. The mixture was stirred at
room temperature under dry nitrogen for 24 h and
concentrated *in vacuo*. The residue was partitioned
between 150 ml CH₂Cl₂ and 100 ml water. The organic
layer was washed with additional water then brine, dried
20 over anh. MgSO₄, filtered, and concentrated to a foam.
The foam was dissolved in a minimum amount of MeOH and
chromatographed on silica gel using CHCl₃-MeOH (95:5) as
mobile phase. The appropriate fractions were combined,
concentrated *in vacuo* to 25 ml, and treated with 1N HCl-
25 Et₂O (10 ml). The resulting gummy mixture was
concentrated to a foam which was triturated with Et₂O,
collected by filtration, washed with additional Et₂O,
and dried to give the desire product in 87% (3.8 g)
yield as a foam; IR(nujol): 2229 (CN), 1723 (CO) cm⁻¹;

¹H NMR(DM. .6 TMS): d 3.4-3.6 (dd, 2H, CH₂ e), 3.6-3.85 (dd, 2H, CH₂-Pyr), [6.91 (d, 2H), 7.25 (m, 3H), 7.61 (m, 3H), Phe-Cl and Phe-CN], [7.37 (dd, 1H), 7.96 (d, 1H), 8.20 (d, 1H), 2,3-Pyr], [7.51 (d, 2H), 8.71 (d, 2H), 1,4-Pyr] ; mass spec m/e 451 (M+1). Anal calcd for C₂₇H₁₉N₄OC1 HCl, MW 487.39: C, 66.54; H, 4.14; N, 11.50. Found:

Example 4




1,3-Dihydro-1-(4-chlorophenyl)-3-(3-pyridinylmethyl)-3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one Dihydrochloride

A mixture of 1,3-dihydro-1-(4-chlorophenyl)-3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one (3.0 g, 8.93 mmol) and 20 ml 1N NaOH was treated with enough MeOH to effect solution. The mixture was treated dropwise with 3-picolyl chloride hydrochloride (1.6 g, 9.82 mmol) in 10 ml water. The mixture was stirred at room temperature for 2 h, and treated with an additional 20 ml 1N NaOH. The mixture was stirred at room temperature for 24 h and concentrated *in vacuo*. The residue was partitioned between 200 ml CH₂Cl₂, washed with brine, dried over MgSO₄, filtered, and treated with 20 ml 1N HCl/Et₂O. The resulting precipitate was

collected by filtration, washed with ether, and dried to give the desired product in 90% (4.0 g) yield; mp 208-211°C, dec.; IR(nujol): 1720 cm^{-1} (CO); ^1H NMR(DMSO- d_6 TMS): d 3.65 [m, 2H, CH_2 -(3-Pyr)], 3.71-3.91 [q, 2H, CH_2 -(4-Pyr)], [7.06 (d, 2H), 7.22 (m, 1H), 7.53 (d, 2H), 7.60 (d, 2H), 7.85 (dd, 1H), 8.04 (dd, 2H), 8.22 (d, 1H), 8.52 (s, 1H), 8.84 (d, 3H), Ar]; mass spec m/e 427 (M+1).

10

Example 5


1,3-Dihydro-1-(4-chlorophenyl)-3-(phenylmethyl)-3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one

15

A mixture of 1,3-dihydro-1-(4-chlorophenyl)-3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one (3.0 g, 8.93 mmol) and 20 ml 1N NaOH was treated with enough MeOH to effect solution. The mixture was treated with benzyl chloride (1.24 g, 9.82 mmol) and stirred at room temperature for 24 h. The resulting solid was collected by filtration, washed with water, and dried in vacuo to give the desired product in 87% (3.30 g) yield; mp 182-185°C; IR(nujol): 1727 cm^{-1} (CO); ^1H NMR(CDCl_3 TMS): d 3.29 (dd, 2H, Phe- CH_2), 3.4-3.7 (g, 2H, Pyr- CH_2), [6.75 (d, J=8.8, 2H), 6.9 (m, 2H), 7.1 (m, 6H), 7.35 (d, J=8.4, 2H), 7.61 (d, J=7.3, 1H), 8.05 (d, J=6.6, 1H),

8.33 (d, 2H, Ar]; mass spec m/e (M+1). Anal
calcd for C₂₆H₂₀N₃OCl, MW 425.92: C, 73.32; H, 4.73; N,
9.87. Found: C, 73.61; H, 4.93; N, 9.83.


5

Example 6

10 **1,3-Dihydro-1-(4-chlorophenyl)-3-(4-
pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one-
3-pentanenitrile**

A solution of 1,3-dihydro-1-(4-chlorophenyl)-3-(4-
pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one (3.0 g,
15 8.93 mmol) in 100 ml dry THF was treated with NaH (0.26
g, 10.72 mmol), stirred at room temperature for 30 min,
and treated with 5-bromovalero-nitrile (1.6 g, 9.87
mmol) in 25 ml dry THF. The mixture was stirred at room
temperature under dry nitrogen for 24 h, and
20 concentrated *in vacuo*. A portion of the residue was
subjected to preparative HPLC to give the desired
product as a slightly yellow oil; IR(nujol): 2246(CN),
1728(CO) cm⁻¹; ¹H NMR(CDCl₃ TMS): δ 1.26 (m, 2H, CH₂-CC-CN),
1.65 (m, 2H, CH₂-C-CN), 2.06, 2.24 (2m, 2H, CH₂-CCC-CN),
25 2.31 (t, 2H, CH₂-CN), [3.17 (d, J=12.8), 3.41 (d,
J=12.8) CH₂-Pyr], [6.98 (d, J=6.4, 2H), 8.32 (d, J=6.4
4-Pyr], [7.07 (d, J=8.6, 2H), 7.44 (d, J=8.6, 2H) 4-Cl-
Phe], 7.13, 7.62, 8.18 (3m, 3H, Pyr); mass spec m/e
417(M+1).

Example 7




5

1,3-Dihydro-1-(4-chlorophenyl)-3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one-3-butanoic acid ethyl ester Hydrochloride

10

By substituting ethyl 4-bromobutyrate in Ex 6, the desire product was obtained as a foam in 22% yield after column chromatography: ^1H NMR (300 MHz, CDCl_3 TMS) δ 1.24 (t, 3H, CH_3), 1.4 (m, 2H, $\text{CH}_2\text{-C-CO}$), 2.0-2.35 (m, 4H, $\text{CH}_2\text{-C-CH}_2\text{-CO}$), [3.07, (d, $J=12.5$, 1H), 3.29 (d, $J=12.5$, 1H, $\text{CH}_2\text{-Pyr}$), 4.11 (q, 2H, OCH_2), [6.76 (d, $J=6$, 2H), 8.31 (d, $J=6$, 2H) 4-Pyr], [7.04 (d, $J=8.8$, 2H), 7.40 (d, $J=8.8$, 2H) 4-Cl-Phe], [7.1 (m, 1H), 7.6 (m, 1H), 8.1 (m, 1H) 2,3-Pyr]; IR (Nujol) 1723 (C=O) cm^{-1} ; MS ($\text{NH}_3\text{-CI}$) m/e 450 ($\text{M}+1$)/100; anal calcd for $\text{C}_{25}\text{H}_{24}\text{N}_3\text{O}_3\text{Cl}$ 2HCl, MW 522.86: C, 57.43; H, 5.01; N, 8.01; found: C, 57.69; H, 4.86; N, 7.86.

Example 8


5 **1,3-Dihydro-1-(4-chlorophenyl)-3-(2-**
 pyridinylmethyl)-3-
 (4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-
 one

10 A suspension of 1,3-dihydro-1-(4-chlorophenyl)-3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one (3.0 g, 8.93 mmol) in 20 ml 1N NaOH was treated with enough MeOH to effect solution. The solution was treated dropwise with a solution of 2-picolylchloride

15 hydrochloride (1.6 g, 9.82 mmol) in 10 ml water over 10 min. The mixture was stirred at room temperature for 16 h, and the resulting solid was collected by filtration, washed with water, and dried. The solid was, recrystallized from CHCl₃-C₆H₁₂ to give the desired

20 product in 79% (3.0 g) yield : m.p. 193-195°; ¹H NMR (300 MHz, CDCl₃ TMS) δ [3.34 (d, J=12, 1H), 3.56 (d, J=12, 1H) CH₂-(2-Pyr)], [3.48 (d, J=14, 1H), 3.78 (d, J=14, 1H) CH₂-(4-Pyr)], [6.95 (m, 1H), 8.0 (m, 1H), 8.27 (d, J=7, 1H) Pyr], [7.0 (m, 6H), 7.5 (m, 2H) 2-Pyr & 4-


25 Cl-Phe)], [7.42 (d, J=7, 2H), 8.32 (d, J=7, 2H) 4-Pyr]; IR (Nujol) 1732 (C=O) cm⁻¹; MS (NH₃-CI) m/e 427(M+1)/100; Analysis calc'd for C₂₅H₁₉N₄OCl H₂O: C, 67.49; H, 4.76; N, 12.59; found: C, 67.38; H, 5.01; N, 12.34.

Example 9

1,3-Dihydro-1-(4-chlorophenyl)-3-(2-pyridinylmethyl)-3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one Dihydrochloride

10

A solution of the free base (**Ex. 8**) in CHCl_3 was treated with excess $\text{HCl}/\text{Et}_2\text{O}$, and the resulting white fluffy solid was collected by filtration, washed with Et_2O , and dried *in vacuo* to give the desired salt in quantitative yield: m.p. $170-175^\circ\text{C}$ dec.; ^1H NMR (300 MHz, DMSO-d_6 TMS) δ [3.62 (d, $J=12.5$, 1H), 3.79 (d, $J=12.5$, 1H), $\text{CH}_2\text{-Pyr}$], 3.78 (s, 2H, $\text{CH}_2\text{-Pyr}$), [7.06 (m, 1H), 7.85 (m, 1H), 8.36 (m, 1H), Pyr], [7.22 (d, $J=8.8$, 2H), 7.57 (m, 4H), 8.72 (d, $J=6.2$, 4-Phe & 4-Pyr)], [7.31 (d, $J=7.3$, 1H), 7.57 (m, 1H), 7.94 (d, $J=4.0$, 1H), 7.96 (d, $J=3.3$, 1H), 2-Pyr]; IR (nujol) 1718 (C=O) cm^{-1} ; MS ($\text{NH}_3\text{-CI}$) m/e 427(M+1).

Example 72

5


N-Cyclohexanemethyl-4-azoxindole

A modification of the procedure described by Goehring, Wolfe, et al. , J. Am. Chem. Soc., **1985**, 107(2), 435-443. A solution of 2-chloro-(N-

10 cyclohexanemethylacetamido)pyridine (2.4 g, 9.0 mmol) in 200 ml dry THF was treated with LDA (3.86 g, 36.0 mmol) and stirred at room temperature for 5 min under dry nitrogen. The resulting reddish solution was transferred to quartz photochemical reaction flask and

15 subjected to uv light generated by a Hanovia lamp #679A36 for 4 h. The mixture was treated with 150 ml sat. NH₄Cl, and the organic layer was separated, dried over MgSO₄, filtered, and concentrated in vacuo to a brown gum in a yield of 92% (1.90 g) : IR (nujol): 1722

20 (C=O) cm⁻¹; MS (NH₃-CI) m/e 231(M+1)/100%; mass spec showed no starting material or des-Cl product of the starting material (M+1 = 233).; The material was used without further purification or characterization.

Example 72

5

1,3-Dihydro-1-cyclohexanemethyl-3,3-bis(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one

A mixture of N-cyclohexanemethyl-4-azoxindole (1.5 g, 6.5 mmol) and 1N NaOH (32.5 ml) was treated with enough MeOH to effect solution. The mixture was stirred at room temperature and treated dropwise over one hour with a solution of 4-picolylchloride hydrochloride (2.3 g, 14.0 mmol) in 25 ml water. The mixture was stirred at room temperature for 24 h and concentrated in vacuo. The residue was triturated with water, and the aqueous phase was discarded. The crude product was column chromatographed on silica gel using CH₂Cl₂ as mobile phase, and appropriate fractions were combined and concentrated to give the desired product as an amorphous brownish solid in 25% yield; tlc homogenous (CHCl₃-MeOH, 9:1), m/e 413(M+1).

Biochemical Test Procedure

Neurotransmitter release assay. The neurotransmitter release activity of the compounds of this invention were determined as reported by
5 Nickolson, et al, (1990) Drug Development Research, 19, 285-300 of a modification of the procedure described by Mulder, et al., Brain Res., 1974, 70, 372.

Male Wistar rats (Charles River) weighing 175-200
10 grams were used. The rats were housed for at least seven days before the experiment in animal facility under 12/12 hour light/dark cycle. Deionized water and standard rat chow (Purina) were available *ad libium*.

Rats were decapitated and brains were dissected
15 immediately. Slices (0.3 mm thick) from the parietal cortex were prepared manually using a recessed Lucite guide and subsequently cut into 0.25 X 0.25 mm squares.

Slices (approximately 100 mg wet weight) were incubated in 10 ml Krebs-Ringer medium (KR) containing
20 NaCl (116 mM), KCl (3 mM), CaCl₂ (1.3 mM), MgCl₂ (1.2 mM), KH₂PO₄ (1.2 mM), Na₂SO₄ (1.2 mM), NaHCO₃ (25.0 mM), and glucose (11.0 mM), to which was added 10 uCi ³H-choline (specific activity approximately 35 Ci/mM; NEN) and 10 mM unlabeled choline to give a final
25 concentration of one micromole. The brain preparations were incubated for 30 min at 37°C under a steady flow of 95% O₂ /5% CO₂. Under these conditions, part of the radioactive choline taken up by the preparation was converted into radioactive acetylcholine (ACh) by the
30 cholinergic nerve endings stored in synaptic vesicles, and released upon depolarization by high potassium ion (K⁺) containing media.

After labelling of the ACh stores, the slices were washed three times with non-radioactive KR medium and

transferred to a superfusion apparatus to measure the drug effects on ACh release. The superfusion apparatus consisted of 10 thermostated glass columns of 5 mm diameter which were provided with GF/F glass fiber filters to support the slices (approximately 10 mg tissue/column). Superfusion was carried out in KR-medium (0.3 ml/min) containing 10 mM hemicholine-3 (HC-3). The HC-3 prevents the reuptake of choline formed during the superfusion from phospholipids and released ACh, which would be converted into unlabeled ACh and released in preference to the pre-formed labelled ACh. The medium was delivered by a 25-channel peristaltic pump (Ismatec by Brinkman) and warmed to 37°C in a thermostated stainless steel coil before entering the superfusion column. Each column was provided with a 4-way slider valve (Beckmann Instruments) which allowed rapid change of low to high K⁺/KR-medium, and with two 10-channel 3-way valves that were used to change from drug-free to drug-containing low and high K⁺/KR-medium.


After 15 min of washout of non-specifically bound radioactivity, collection of 4 min fractions was initiated. After three 4 min collections, the original medium was changed to a KR-medium in which the KCl concentration had been increased to 25 mM (high K⁺ medium) (S1). Depolarization-induced stimulation of release by high K⁺/KR-medium lasted for 4 min. Drug free low and high K⁺/KR-media were then substituted by drug- and vehicle-containing low- and high-K⁺/KR-medium, and superfusion was continued for three 4 min collections with low K⁺/KR-medium, one 4 min collection with high K⁺/KR-medium (S2), and two 4 min collections with low K⁺/KR-medium.








Drug was added to the media by 100-fold dilutions of appropriate concentrations of the drug (in 0.9% saline) with either low- or high-K⁺/KR-medium.













All superfusion fractions were collected in liquid scintillation counting vials. After superfusion, the slices were removed from the superfusion columns and extracted with 1.0 ml of 0.1 N HCl. Liquiscint (NEN) counting fluid (12 ml) was added to superfusion fractions and extracts, and the samples were counted in a Packard Tricarb Liquid Scintillation Counter. No corrections were made for quenching.











The ratio of **S2/S1** (as compared to controls where no drug was present during S2) was a measure of the ability of the drug to enhance or depress stimulus-induced acetylcholine release.

Table I













Cmpd	Core	R ¹	%Yield	mp, °C	%ACh Rel	
					@ 10 mM	
1		4-Pyr-CH ₂ HCl 0.5 H ₂ O	27	184-185	423	












2		4-Pyr-CH ₂ HCl	64	137 dec.	626
3		3-CN-Phe-CH ₂	87	foam	537
4		3-Pyr-CH ₂ HCl	90	208-211 dec.	299
5		Phe-CH ₂	87	182-185	257
6		(CH ₂) ₄ -CN	isolat- ed by prep HPLC	oil	
7		(CH ₂) ₃ -CO ₂ Et	22	foam	
8		2-Pyr-CH ₂	79	193-194	









9		2-Pyr-CH ₂ 2 HCl	100	175 dec
10		4-Pyr-CH ₂		
11				
12		4-Pyr-CH ₂		
13		4-Pym-CH ₂		
14		4-Pyr-CH ₂		
15		4-Pyr-CH ₂		
16		4-Pyr-CH ₂		
17		4-Pyr-CH ₂		
18		4-Pyr-CH ₂		
19		4-Pyr-CH ₂		

20		4-Pyr-CH ₂
21		4-Pyr-CH ₂
22		4-Pyr-CH ₂
23		4-Pyr-CH ₂
24		4-Pyr-CH ₂
25		4-Pyr-CH ₂
26		4-Pyr-CH ₂
27		4-Pyr-CH ₂
28		4-Pyr-CH ₂
29		4-Pyr-CH ₂

30		4-Pyr-CH ₂
31		4-Pyr-CH ₂
32		4-Pyr-CH ₂
33		(CH ₂) ₂ -CO ₂ Et
34		(CH ₂) ₃ -CO ₂ Et
35		(CH ₂) ₄ -CO ₂ Et
36		(CH ₂) ₃ -CN
37		(CH ₂) ₄ -CN
38		(CH ₂) ₅ -CN
39		(CH ₂) ₃ -CO ₂ Me
40		(CH ₂) ₃ - CO ₂ (n-Pr)
41		(CH ₂) ₃ - CO ₂ (i-Pr)

42		(CH ₂) ₃ - CO ₂ (n-Bu)
43		(CH ₂) ₃ - CO ₂ (t-Bu)
44		(CH ₂) ₃ - CO ₂ C ₆ H ₁₁
45		(CH ₂) ₃ - CO ₂ CH ₂ C ₆ H ₅
46		(CH ₂) ₃ -CO ₂ H
47		(CH ₂) ₃ - SO ₂ NH ₂
48		(CH ₂) ₃ - SO ₂ NMe ₂
49		(CH ₂) ₃ -OAc
50		4-Pyr-CH ₂
51		4-Pyr-CH ₂
52		4-Pyr-CH ₂
53		4-Pyr-CH ₂

54		4-Pyr-CH ₂
55		4-Pyr-CH ₂
56		4-Pyr-CH ₂
57		4-Pyr-CH ₂
58		4-Pyr-CH ₂
59		4-Pyr-CH ₂
60		4-Pyr-CH ₂
61		4-Pyr-CH ₂
62		4-Pyr-CH ₂
63		4-Pyr-CH ₂
64		4-Pyr-CH ₂

65		4-Pyr-CH ₂			
66		4-Pyr-CH ₂			
67		4-Pyr-CH ₂			
68		4-Pyr-CH ₂			
69		4-Pyr-CH ₂			
70		4-Pyr-CH ₂			
71		4-Pyr-CH ₂			
72		4-Pyr-CH ₂	25	amorphous	>150

Behavioral Test Procedure.

Rat Passive Avoidance (PA) Hypoxia Induced Amnesia:
Unfasted male CD rats, weighing between 165-210 g were
5 trained in a PA apparatus using the following procedure:
rats were placed in the clear side of the two
compartment chamber and allowed 90 seconds to enter the
dark compartment. Ten seconds after entering the dark
chamber, a 3 second foot shock (1.0 mA) was applied to
10 the grid floor followed by an additional 10 second
delay, and another 3 second foot shock was applied.
Retentions were tested 4 hours later. The rats were
allowed 300 seconds to enter the dark compartment; time
was taken. Memory disruption was induced by exposing
15 the rats to a gas mixture containing 6.5% oxygen
supplemented with nitrogen for 30 minutes prior to
passive avoidance training. Doses of the test compound
were administered (0.1 ml/100 g s.c.) relative to time
of PA training. Using this method, **Example 1** was shown
20 to have the following latency as compared to control:

Example 1 ED₁₅₀, s.c. = 1.3 mg/kg

Utility

The foregoing test results suggest that the compounds of this invention have utility in the treatment of cognitive disorders and/or neurological function deficits and/or mood and mental disturbances in patients suffering from nervous system disorders like Alzheimer's disease, Parkinson's disease, senile-dementia, multi-infarct dementia, Huntington's disease, mental retardation, Myasthenia Gravis, etc. Compounds of this invention can be administered to treat said deficiencies by any means that produces contact of the active agent with the agent's site of action in the body of a mammal. The compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals either as individual therapeutic agent or in combination of therapeutic agents. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage administered will vary depending on the use and known factors such as the pharmacodynamic character of the particular agent, and its mode and route of administration; the recipient's age, weight, and health; nature and extent of symptoms; kind of concurrent treatment; frequency of treatment; and the desired effect. For use in the treatment of said diseases or conditions, the compounds of this invention can be orally administered daily at a dosage of the active ingredient of 0.001 to 100 mg/kg of body weight. Ordinarily, a dose of 0.01 to 10 mg/kg/day in divided doses one to four times a day, or in sustained release

formulation was effective in obtaining the desired pharmacological effect.

Dosage forms (compositions) suitable for administration contain from about 1 mg to about 100 mg of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of about 0.5 to 95% by weight based on the total weight of the composition,

The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders; or in liquid forms such as elixirs, syrups, and/or suspensions. The compounds of this invention can also be administered parenterally in sterile liquid dose formulations.

Gelatin capsules can be used to contain the active ingredient and a suitable carrier such as but not limited to lactose, starch, magnesium stearate, steric acid, or cellulose derivatives. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of time. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste, or used to protect the active ingredients from the atmosphere, or to allow selective disintegration of the tablet in the gastrointestinal tract.

Liquid dosage forms for oral administration can contain coloring and flavoring agents to increase patient acceptance.

In general, water, pharmaceutically acceptable oils, saline, aqueous dextrose (glucose), and related sugar solutions and glycols, such as propylene glycol or polyethylene glycol, are suitable carriers for parenteral solutions. Solutions for parenteral

administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents, such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or in combination, are suitable stabilizing agents. Also used are citric acid and its salts, and EDTA. In addition, parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences", A. Osol, a standard reference in this field.

Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:

Capsules

A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 mg of powdered active ingredient, 150 mg lactose, 50 mg cellulose, and 6 mg magnesium stearate.

Soft Gelatin Capsules

A mixture of active ingredient in a digestible oil such as soybean, cottonseed oil, or olive oil was prepared and injected by means of a positive displacement was pumped into gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules are washed and dried.


Tablets

A large number of tablets are prepared by conventional procedures so that the dosage unit was 100 mg of active ingredient, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch, and 98.8 mg

lactose. Appropriate coatings may be applied to increase palatability or delayed absorption.

What is Claimed is:

1. A compound of the Formula I




5

Formula I

or a pharmaceutically acceptable salt thereof

wherein **A** is a heteroaromatic system selected from the group consisting essentially of


10



and wherein

2. A compound of claim 1 wherein

A is



R^1 is $(CH_2)_m-W$ or $(CH_2)_n-R^4$;

5 R^2 is alkyl of 1-7 carbon atoms, benzyl substituted with 0-3 R^4 , or phenyl substituted with 0-3 R^5 ;

R^3 is H, alkyl of 1-6 carbon atoms, halogen, CN, OR^7 , $N(R^7R^8)$, $S(O)PR^7$, NO_2 , or CF_3 ;

10 R^4 is CO_2R^7 , $CON(R^7R^8)$, CN, OR^7 , $N(R^7R^8)$, $S(O)PR^7$, F, Cl, Br, NO_2 , or COR^7 ;

R^5 is CO_2R^7 , $CON(R^7R^8)$, CN, OR^7 , $N(R^7R^8)$, $S(O)PR^7$, F, Cl, Br, NO_2 , COR^7 , or CF_3 ;

R^6 is H, alkyl of 1-4 carbon atoms, phenyl, or benzyl;

15 R^7 and R^8 independently are H, or alkyl of 1-6 carbon atoms;

W is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, tetrahydrofuranyl, thienyl, or phenyl optionally substituted with 0-2 R^5 ;

m is 1 to 4;

20 n is 1 to 6; and

p is 0 to 2.

3. A compound of claim 2 wherein

A is



25 R^1 is $(CH_2)_m-W$ or $(CH_2)_n-R^4$;

R^2 is alkyl of 1-7 carbon atoms, benzyl substituted with 0-3 R^4 , or phenyl substituted with 0-3 R^5 ;

30 R^3 is H, alkyl of 1-4 carbons, halogen, CN, OR^7 , $N(R^7R^8)$, $S(O)PR^7$, NO_2 , or CF_3 ;

R^4 is CO_2R^7 , $CON(R^7R^8)$, CN, $S(O)PR^7$, or COR^7 ;


- R^5 is CO_2R^7 , $CON(R^7R^8)$, CN , OR^7 , $N(R^7R^8)$, $S(O)pR^7$, F , Cl ,
 Br , NO_2 , COR^7 , or CF_3 ;
 R^6 is H , alkyl of 1-4 carbons, phenyl, or benzyl;
 R^7 and R^8 independently are H , or alkyl of 1-6 carbons;
 5 W is pyridyl, pyrimidinyl, tetrahydrofuranyl;
 m is 1 to 4;
 n is 1 to 6; and
 p is 1 or 2.
- 10 4. A compound of claim 3 wherein
 R^1 is 2,3 or 4-pyridyl- CH_2 -, 4-pyrimidinyl- CH_2 -, 3-CN
 phenyl- CH_2 -, phenyl- CH_2 -, $-(CH_2)_4$ CN, or $-(CH_2)_3CO_2$ Et;
 R^2 is phenyl; and
 R^3 is H or Cl .
- 15 5. A compound of claim 4 wherein
 R^1 is 3 or 4-pyridyl- CH_2 -, 3-CN phenyl- CH_2 or phenyl- CH_2 .
- 20 6. The compound of claim 1 which is 1,3-Dihydro-1-(4-
 phenyl-3,3-bis(4-pyridinylmethyl)-2H-pyrrolo[2,3-
 b]pyridin-2-one Dihydrochloride.
- 25 7 The compound of claim 1 which is 1,3-Dihydro-1-(4-
 chlorophenyl)-3,3-bis(4-pyridinylmethyl)-2H-pyrrolo
 [2,3-b]pyridin-2-one Dihydrochloride.
- 30 8. The compound of claim 1 which is 1,3-Dihydro-1-(4-
 chlorophenyl)-3-(3-cyanophenyl)-3-(4-pyridinylmethyl)-
 2H-pyrrolo[2,3-b]pyridin-2-one Dihydrochloride.
9. The compound of claim 1 which is 1,3-Dihydro-1-(4-
 chlorophenyl)-3-(3-pyridinylmethyl)-3-(4-
 pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one
 Dihydrochloride.

10. The compound of claim 1 which is 1,3-Dihydro-1-(4-chlorophenyl)-3-(phenylmethyl)-3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one.

5

11. A pharmaceutically composition comprising an amount of a compound of claim 1 effective to treat cognitive disorders and a pharmaceutically acceptable carrier.


10 12. A pharmaceutical composition as recited in claim 11 wherein the compound is of the formula



Formula I

or a pharmaceutically acceptable salt thereof, wherein

15 A is



R¹ is (CH₂)_m-W or (CH₂)_n-R⁴;

R² is alkyl of 1-7 carbon atoms, benzyl substituted with 0-3 R⁴, or phenyl substituted with 0-3 R⁵;

20 R³ is H, alkyl of 1-6 carbon atoms, halogen, CN, OR⁷, N(R⁷R⁸), S(O)pR⁷, NO₂, or CF₃;

R⁴ is CO₂R⁷, CON(R⁷R⁸), CN, OR⁷, N(R⁷R⁸), S(O)pR⁷, F, Cl, Br, NO₂, or COR⁷;

25 R⁵ is CO₂R⁷, CON(R⁷R⁸), CN, OR⁷, N(R⁷R⁸), S(O)pR⁷, F, Cl, Br, NO₂, COR⁷, or CF₃;

R⁶ is H, alkyl of 1-4 carbon atoms, phenyl, or benzyl;

R⁷ and R⁸ independently are H, or alkyl of 1-6 carbon atoms;

W is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl,
pyrazolyl, tetrahydrofuranyl, thienyl, or phenyl
optionally substituted with 0-2 R⁵;


m is 1 to 4;

5 n is 1 to 6; and

p is 0 to 2.

13. A pharmaceutical composition as recited in claim 12
wherein the compound is of the formula

10



Formula I

or a pharmaceutically acceptable salt thereof, wherein

15 A is



R¹ is (CH₂)_m-W or (CH₂)_n-R⁴;

20 R² is alkyl of 1-7 carbon atoms, benzyl substituted with
0-3 R⁴, or phenyl substituted with 0-3 R⁵;

R³ is H, alkyl of 1-4 carbons, halogen, CN, OR⁷,
N(R⁷R⁸), S(O)pR⁷, NO₂, or CF₃;

25

R⁴ is CO₂R⁷, CON(R⁷R⁸), CN, S(O)pR⁷, or COR⁷;

R⁵ is CO₂R⁷, CON(R⁷R⁸), CN, OR⁷, N(R⁷R⁸), S(O)pR⁷, F, Cl,
Br, NO₂, COR⁷, or CF₃;

30

R⁶ is H, alkyl of 1-4 carbons, phenyl, or benzyl;

R⁷ and R⁸ independently are H, or alkyl of 1-6 carbons;

35

W is pyridyl, pyrimidinyl, tetrahydrofuranyl;

m is 1 to 4;

n is 1 to 6; and

5

p is 1 or 2.

14. A pharmaceutical composition of claim 12 wherein the compound is 1,3-Dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one Dihydrochloride.


15. A pharmaceutical composition of claim 12 wherein the compound is 1,3-Dihydro-1-(4-chlorophenyl)-3,3-bis(4-pyridinylmethyl)-2H-pyrrolo [2,3-b]pyridin-2-one Dihydrochloride.

16. A pharmaceutical composition of claim 12 wherein the compound is 1,3-Dihydro-1-(4-chlorophenyl)-3-(3-cyanophenyl)-3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one Dihydrochloride.

17. A pharmaceutical composition of claim 12 wherein the compound is 1,3-Dihydro-1-(4-chlorophenyl)-3-(3-pyridinylmethyl)-3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one Dihydrochloride.


18. A pharmaceutical composition of claim 12 wherein the compound is 1,3-Dihydro-1-(4-chlorophenyl)-3-(phenylmethyl)-3-(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one.

19. A method of treating cognitive disorders in a mammal, aid method comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the formula



Formula I

or a pharmaceutically acceptable salt thereof where **A** is
 5 a heteroaromatic system selected from the group
 consisting essentially of



10 and wherein

R^1 is $(CH_2)_m-W$ or $(CH_2)_n-R^4$;

R^2 is alkyl of 1-7 carbon atoms, benzyl substituted with
 0-3 R^4 , or phenyl substituted with 0-3 R^5 ;

R^3 is H, alkyl of 1-6 carbon atoms, halogen, CN, OR^7 ,
 15 $N(R^7R^8)$, $S(O)PR^7$, NO_2 , or CF_3 ;

R^4 is CO_2R^7 , $CON(R^7R^8)$, CN, OR^7 , $N(R^7R^8)$, $S(O)PR^7$, F, Cl,
 Br, NO_2 , or COR^7 ;

R^5 is CO_2R^7 , $CON(R^7R^8)$, CN, OR^7 , $N(R^7R^8)$, $S(O)PR^7$, F, Cl,
 Br, NO_2 , COR^7 , or CF_3 ;

20 R^6 is H, alkyl of 1-4 carbon atoms, phenyl, or benzyl;

R^7 and R^8 independently are H, or alkyl of 1-6 carbon atoms;

W is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, tetrahydrofuranyl, thienyl, or phenyl


5 optionally substituted with 0-2 R^5 ;

m is 1 to 4;

n is 1 to 6; and

p is 0 to 2.

10 20. The method of claim 19 wherein the compound of the formula




Formula I

or a pharmaceutically acceptable salt thereof,

15 wherein

A is



R^1 is $(CH_2)_m-W$ or $(CH_2)_n-R^4$;

20 R^2 is alkyl of 1-7 carbon atoms, benzyl substituted with 0-3 R^4 , or phenyl substituted with 0-3 R^5 ;

R^3 is H, alkyl of 1-6 carbon atoms, halogen, CN, OR^7 , $N(R^7R^8)$, $S(O)pR^7$, NO_2 , or CF_3 ;

R^4 is CO_2R^7 , $CON(R^7R^8)$, CN, OR^7 , $N(R^7R^8)$, $S(O)pR^7$, F, Cl, Br, NO_2 , or COR^7 ;

25 R^5 is CO_2R^7 , $CON(R^7R^8)$, CN, OR^7 , $N(R^7R^8)$, $S(O)pR^7$, F, Cl, Br, NO_2 , COR^7 , or CF_3 ;

R^6 is H, alkyl of 1-4 carbon atoms, phenyl, or benzyl;

R^7 and R^8 independently are H, or alkyl of 1-6 carbon atoms;

W is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, tetrahydrofuranyl, thienyl, or phenyl


5 optionally substituted with 0-2 R^5 ;

m is 1 to 4;

n is 1 to 6; and

p is 0 to 2.

10 21. The method of claim 21 wherein the compound is of the formula



Formula I

or a pharmaceutically acceptable salt thereof, wherein

15

A is



R^1 is $(CH_2)_m-W$ or $(CH_2)_n-R^4$;

R^2 is alkyl of 1-7 carbon atoms, benzyl substituted with 0-3 R^4 , or phenyl substituted with 0-3 R^5 ;

20

R^3 is H, alkyl of 1-4 carbons, halogen, CN, OR^7 , $N(R^7R^8)$, $S(O)pR^7$, NO_2 , or CF_3 ;

R^4 is CO_2R^7 , $CON(R^7R^8)$, CN, $S(O)pR^7$, or COR^7 ;

R^5 is CO_2R^7 , $CON(R^7R^8)$, CN, OR^7 , $N(R^7R^8)$, $S(O)pR^7$, F, Cl,

25

Br, NO_2 , COR^7 , or CF_3 ;

R^6 is H, alkyl of 1-4 carbons, phenyl, or benzyl;

R^7 and R^8 independently are H, or alkyl of 1-6 carbons;

W is pyridyl, pyrimidinyl, tetrahydrofuranyl;

m is 1 to 4;

n is 1 to 6; and
p is 1 or 2.

22. The method of claim 20 wherein the compound is
5 selected from the group consisting essentially of 1,3-
Dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-2H-
pyrrolo[2,3-b]pyridin-2-one Dihydrochloride,

10 1,3-Dihydro-1-(4-chlorophenyl)-3,3-bis(4-
pyridinylmethyl)-2H-pyrrolo [2,3-b]pyridin-2-one
Dihydrochloride,

15 1,3-Dihydro-1-(4-chlorophenyl)-3-(3-cyanophenyl)-3-
(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one
Dihydrochloride,

20 1,3-Dihydro-1-(4-chlorophenyl)-3-(3-
pyridinylmethyl)-3-(4-pyridinylmethyl)-2H-
pyrrolo[2,3-b]pyridin-2-one Dihydrochloride,

1,3-Dihydro-1-(4-chlorophenyl)-3-(phenylmethyl)-3-
(4-pyridinylmethyl)-2H-pyrrolo[2,3-b]pyridin-2-one.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JS 93/08563

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C07D471/04 A61K31/435 C07D487/04 C07D491/048 C07D495/04
 C07D513/04 C07D498/04 A61K31/495 //(C07D471/04, 221:00,
 209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 241 006 (DU PONT) 14 October 1987 see page 36, line 17 - line 25; claim 1 & US,A,4 760 083 (J. M. MYERS ET AL.) cited in the application -----	1,11



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search

9 December 1993

Date of mailing of the international search report

12. 01. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/ 08563

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
The search has been carried out as if R1,R2 and R3 in claim 1 had been defined as in claim 2.
Although claims 19-22 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JS 93/08563

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0241006	14-10-87	US-A- 4760083	26-07-88
		AU-B- 599370	19-07-90
		AU-A- 7133487	15-10-87
		CA-A- 1301151	19-05-92
		JP-A- 62277381	02-12-87
		SU-A- 1575936	30-06-90
		US-A- 5173489	22-12-92
		US-A- 4876259	24-10-89

US-A-4760083	26-07-88	AU-B- 599370	19-07-90
		AU-A- 7133487	15-10-87
		CA-A- 1301151	19-05-92
		EP-A, B 0241006	14-10-87
		US-A- 4876259	24-10-89
		US-A- 5173489	22-12-92
		JP-A- 62277381	02-12-87
		SU-A- 1575936	30-06-90
